Competition intensifying for diabetes subjects; Acurian

Competition intensifying for diabetes subjects; Acurian


Acurian, a company that specializes in patient recruiting, has reached a significant business milestone with the addition of more than 50 percent of the country's type 2 diabetes population to its database. 


Approximately 8 million of the estimated 16 million diagnosed type 2 or adult-onset diabetes are already on the company's books. The business maintains a database of almost 40 million patients in total.

According to Rick Malcolm, PhD, CEO of Acurian, "It should come as no surprise that diabetes is one of the most strong indications in our database. However, given the fierce rivalry for research participants in this therapeutic field, the fact that more than half of the nation's type 2 diabetics are present and open to learning about clinical trials is definitely important to note. 

According to him, Acurian can assist trial sponsors in gaining access to huge numbers of diabetic patients so they can successfully recruit the right subsets, such as people of color who have the disease or those who have type 1 diabetes.

Comments

Popular posts from this blog

 Role of Blockchain in Healthcare Data Management

Demystifying AI in Drug Discovery: Transforming Pharma R&D